IRADIMED CORP
IRADIMED CORP
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 59 | 56 | 51 | 57 | 53 | 50 | 52 | 52 | 49 | 45 | 50 | 47 | |||||
Accounts Receivable Net Current | 13 | 13 | 14 | 14 | 11 | 13 | 11 | 10 | 12 | 13 | 12 | 13 | |||||
Inventory Net | 12 | 12 | 12 | 12 | 11 | 11 | 10 | 11 | 12 | 13 | 13 | 12 | |||||
Prepaid Expense And Other Assets Current | 1 | 2 | 5 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | |||||
Prepaid Taxes | 1 | 3 | - | 2 | 0 | - | - | - | - | - | - | - | |||||
Assets Current | 87 | 86 | 81 | 85 | 77 | 75 | 75 | 74 | 74 | 72 | 76 | 72 | |||||
Property Plant And Equipment Net | 24 | 24 | 24 | 24 | 23 | 20 | 17 | 14 | 10 | 9 | 9 | 9 | |||||
Finite Lived Intangible Assets Net | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | |||||
Operating Lease Right Of Use Asset | - | - | - | - | - | 0 | 0 | 0 | 0 | 2 | 2 | 2 | |||||
Deferred Income Tax Assets Net | 0 | 0 | 0 | 2 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | |||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 115 | 114 | 109 | 115 | 106 | 102 | 98 | 94 | 90 | 88 | 92 | 87 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 2 | 3 | |||||
Employee Related Liabilities Current | 3 | 2 | 3 | 4 | 3 | 2 | 4 | 3 | 3 | 2 | 3 | 2 | |||||
Accrual For Taxes Other Than Income Taxes Current | 1 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Product Warranty Accrual Classified Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Contract With Customer Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 2 | |||||
Dividends Payable Current | - | - | - | - | - | - | - | - | - | - | 8 | - | |||||
Operating Lease Liability Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Liabilities Current | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accrued Income Taxes Current | 0 | 4 | 2 | 3 | - | 1 | - | - | - | 1 | 0 | - | |||||
Liabilities Current | 9 | 12 | 10 | 13 | 9 | 8 | 9 | 8 | 7 | 8 | 16 | 8 | |||||
Contract With Customer Liability Noncurrent | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Operating Lease Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 2 | 2 | 2 | |||||
Liabilities | 13 | 16 | 14 | 16 | 12 | 12 | 12 | 11 | 10 | 12 | 21 | 13 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 32 | 31 | 30 | 32 | 31 | 31 | 30 | 30 | 29 | 29 | 28 | 28 | |||||
Retained Earnings Accumulated Deficit | 70 | 67 | 64 | 66 | 63 | 59 | 57 | 54 | 50 | 47 | 43 | 47 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Stockholders Equity | 102 | 99 | 95 | 98 | 94 | 90 | 87 | 83 | 80 | 76 | 71 | 75 | |||||
Liabilities And Stockholders Equity | 115 | 114 | 109 | 115 | 106 | 102 | 98 | 94 | 90 | 88 | 92 | 87 | |||||
Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | |||||
Common Stock Shares Issued | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |||||
Shares Outstanding | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.92% | 6.04% | 11.59% | - | - | - | - | - | - | - | - | - |
| 2025 | 11.02% | 16.69% | 8.03% | 10.07% | 6.83% | 11.24% | 11.05% | 16.70% | 20.78% | -1.38% | -10.17% | -6.49% |
| 2024 | -3.01% | -1.82% | 3.44% | -0.34% | 4.32% | 12.64% | 8.34% | 11.23% | 20.43% | 0.04% | 1.78% | -2.17% |
| 2023 | - | - | - | -1.82% | -9.83% | -19.29% | -4.44% | 4.26% | -0.15% | 2.46% | -2.84% | -0.05% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 9.46 | 7.13 | 7.98 | 6.64 | 8.78 | 8.87 | 8.84 | 9.21 | 9.87 | 9.44 | 4.65 | 9.13 | |||||
| Quick Ratio | 7.97 | 6.02 | 6.37 | 5.63 | 7.29 | 7.44 | 7.38 | 7.70 | 8.11 | 7.64 | 3.80 | 7.55 | |||||
| Working Capital | 77.56M | 74.30M | 71.02M | 72.12M | 68.56M | 66.66M | 66.73M | 66.22M | 66.12M | 64.27M | 59.67M | 64.05M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.13 | 0.16 | 0.15 | 0.17 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.16 | 0.29 | 0.17 | |||||
| Debt Ratio | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.14 | 0.23 | 0.15 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.78 | 0.80 | 0.81 | 0.77 | 0.79 | 0.79 | 0.77 | 0.79 | 0.81 | 0.83 | 0.74 | 0.75 | |||||
| Days Sales Outstanding TTM | 50.97 | 55.25 | 52.74 | 54.91 | 53.77 | 62.49 | 56.76 | 59.25 | 60.50 | 66.22 | 70.98 | 67.91 | |||||
| Receivables Turnover TTM | 7.16 | 6.61 | 6.92 | 6.65 | 6.79 | 5.84 | 6.43 | 6.16 | 6.03 | 5.51 | 5.14 | 5.37 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | 1.79 | 1.83 | 1.75 | 1.65 | 1.61 | 1.54 | 1.50 | 1.46 | 1.46 | 1.41 | 1.35 | 1.28 | |||||
| Free Cash Flow Per Share TTM | 1.96 | 1.91 | 1.35 | 1.16 | 1.12 | 1.15 | 1.39 | 1.41 | 1.07 | 0.90 | 0.48 | 0.43 | |||||
| Dividend Per Share TTM | 1.24 | 1.21 | 1.18 | 0.66 | 0.64 | 0.62 | 1.08 | 0.93 | 0.78 | 0.63 | 1.05 | 1.05 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 75.86% | 76.84% | 76.75% | 77.07% | 76.96% | 76.91% | 76.94% | 77.14% | 77.21% | 76.57% | 76.50% | 76.17% | |||||
| Operating Profit Margin TTM | 31.91% | 32.40% | 31.20% | 30.87% | 30.67% | 30.14% | 29.99% | 29.91% | 30.86% | 30.70% | 30.56% | 30.38% | |||||
| Net Profit Margin TTM | 26.70% | 27.36% | 26.82% | 26.31% | 26.61% | 26.32% | 26.26% | 26.12% | 26.83% | 26.48% | 26.22% | 25.93% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 11.21% | 14.81% | 14.43% | 12.91% | 11.73% | 11.04% | 11.71% | 13.23% | 16.05% | 19.87% | 23.00% | 25.17% | |||||
| Net Income Growth (1Y) | 11.61% | 19.34% | 16.88% | 13.73% | 10.79% | 10.38% | 11.87% | 14.09% | 26.95% | 30.37% | 34.02% | 25.13% | |||||
| EPS Growth (1Y) | 11.01% | 18.70% | 16.40% | 13.27% | 10.35% | 9.94% | 11.28% | 13.48% | 26.26% | 29.66% | 33.59% | 24.76% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | 52.87 | 51.88 | 54.69 | 42.15 | 36.22 | 33.08 | 35.43 | 33.36 | 29.01 | 30.10 | 33.70 | 32.71 | |||||
| P/B TTM | 11.98 | 12.43 | 12.99 | 9.08 | 7.93 | 7.27 | 7.85 | 7.45 | 6.79 | 7.09 | 8.11 | 7.16 | |||||
| P/S TTM | 14.12 | 14.20 | 14.67 | 11.09 | 9.64 | 8.71 | 9.30 | 8.71 | 7.78 | 7.97 | 8.84 | 8.48 | |||||
| Market Cap | 1.22B | 1.22B | 1.23B | 892.88M | 748.12M | 654.49M | 681.49M | 621.37M | 540.88M | 539.49M | 579.43M | 534.07M | |||||
| Enterprise Value | 1.16B | 1.17B | 1.18B | 836.35M | 695.12M | 604.16M | 629.25M | 569.65M | 492.34M | 494.36M | 529.67M | 487.33M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 25.12M | 24.47M | 17.18M | 14.75M | 14.21M | 14.60M | 17.62M | 17.80M | 13.58M | 11.39M | 6.02M | 5.42M | |||||
| Net Debt | -59.08M | -56.37M | -51.16M | -56.53M | -53.00M | -50.33M | -52.23M | -51.72M | -48.54M | -45.13M | -49.76M | -46.75M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
IRADIMED CORP (IRMD) — SEC Financial Statements & Analysis
IRADIMED CORP (IRMD) is a surgical & medical instruments & apparatus company, incorporated in DE. IRADIMED CORP trades on Nasdaq as: IRMD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), IRADIMED CORP reported a 11.21% year-over-year revenue growth, a Gross Profit Margin of 75.86% (TTM), a Debt-to-Equity ratio of 0.13x, a Price-to-Sales (P/S) ratio of 14.12x (TTM), a Price-to-Book (P/B) ratio of 11.98x (TTM), at a market cap of $1.22B. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 11.21%
- Gross Profit Margin TTM
- 75.86%
- Debt To Equity
- 0.13x
- P/S TTM
- 14.12x
- P/B TTM
- 11.98x
- Market Cap
- $1.22B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IRADIMED CORP in?
IRADIMED CORP (IRMD) operates in the Surgical & Medical Instruments & Apparatus industry.
What is IRMD's market cap?
IRADIMED CORP (IRMD) has a market capitalization of $1.22B as of 2026-06-30.
What is IRMD's P/E ratio?
IRADIMED CORP (IRMD)'s trailing twelve month P/E ratio is 52.87x as of 2026-06-30.
What exchange does IRMD trade on?
IRADIMED CORP (IRMD) trades on the Nasdaq.
Where is IRADIMED CORP incorporated?
IRADIMED CORP is incorporated in DE.